Formulation and Evaluation of Benazepril Emulsomes Containing Transdermal Patch

Abstract

Transdermal drug delivery is an alternative route of administration that offers avoidance of the associated drawbacks of orally and parenterally administered hydrophobics. However, owing to the extremely specific set of physicochemical characteristics required for passive transdermal drug permeation. The purpose of this research was to develop a transdermal therapeutic system containing drug Benazepril hydrochloride (BZ). Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat. Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Emulsomes containing phosphatidylcholine (soya-lecithine), cholesterol and either of the solid lipid were prepared and optimized for the lipid ratios. Hence it was desired to develop formulations which would be avoid the problems of toxicity and rapid elimination of drug. The transdermal route for the treatment eliminates major side effects and showed better effect to diseased suffering person. The aim of present work is to development of new approach as matrix type polymeric transdermal patch for management of hypertension of cardiac patients.